Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed President Ubl Brings Detailed Policy Approach To Industry Agenda

This article was originally published in The Gray Sheet

Executive Summary

The choice of Stephen Ubl as AdvaMed's president & CEO reflects board members' preference for detailed knowledge of the industry over mere political clout

You may also be interested in...



PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise

Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.

PhRMA CEO: Ubl Pick Would Bring User Fee, Reimbursement Expertise

Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill, but also developing reputation of his own as a policy wonk.

AdvaMed Launches National Search For New CEO As Ubl Plans Departure

AdvaMed CEO Steve Ubl is leaving the device trade association to take the helm of the Pharmaceutical Research and Manufacturers of America. Ubl has led AdvaMed for 10 years, raising the profile of the device industry among policymakers, fighting perception battles and, of course, opposing the device tax.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel